FIELD: medicine.
SUBSTANCE: present invention refers to medicine, namely to dermatology and surgery, and concerns an agent for wound and ulcer healing. That is ensured by local application of a composition containing a granulocyte-macrophage colony-stimulating factor (GM-CSF) and a phosphomycin calcium salt. GM-CSF is presented in the form of molginostim or sargraimostima and ranges from 1 mcg/g to 10 mcg/g.
EFFECT: such composition of composition provides higher rate of healing of wounds, ulcers, bedsores, burns and other damages of skin or mucous membranes due to regenerating, activating anti-infectious immunity and bactericidal action of components of composition in the absence of side effects.
6 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RESPIRATORY INTRODUCTION OF ACTIVATED PROTEIN C IN INFLAMMATORY CONDITIONS INVOLVING RESPIRATORY TRACT | 2006 |
|
RU2496515C2 |
| RESPIRATORY INTRODUCTION OF TISSUE FACTOR PATHWAY INHIBITOR IN INFLAMMATORY CONDITIONS INVOLVING RESPIRATORY TRACT | 2006 |
|
RU2496516C2 |
| BACTERIOPHAGE-DERIVED ANTIMICROBIAL POLYPEPTIDES AND THEIR USE AGAINST GRAM-NEGATIVE BACTERIA | 2019 |
|
RU2804774C2 |
| VACCINATION USING THE ALPHA 3 DOMAIN OF MICA/B FOR CANCER TREATMENT | 2016 |
|
RU2747296C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
| LYSINE POLYPEPTIDES ACTIVE AGAINST GRAM-NEGATIVE BACTERIA | 2016 |
|
RU2724545C2 |
| MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO CSF-1R | 2020 |
|
RU2751249C1 |
| NEW ANTIBODIES AND NUCLEOTIDE SEQUENCES AND THEIR USE | 2019 |
|
RU2802450C2 |
| ANTIBODIES, SPECIFIC TO HYPERPHOSPHORYLATED TAU-PROTEIN, AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2727911C2 |
